The cost-effectiveness of brigatinib in adult patients with ALK inhibitor–naive ALK-positive non–small cell lung cancer from a US perspective

por Cranmer, Holly, Kearns, Isabella, Young, Melanie, Humphries, Michael J, Trueman, David
Publicado 2022

Omalizumab Improves Quality of Life and Asthma Control in Chinese Patients With Moderate to Severe Asthma: A Randomized Phase III Study

por Li, Jing, Kang, Jian, Wang, Changzheng, Yang, Jing, Wang, Linda, Kottakis, Ioannis, Humphries, Michael, Zhong, Nanshan
Publicado 2016

Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis

por Vogelmeier, Claus, Zhong, Nanshan, Humphries, Michael J, Mezzi, Karen, Fogel, Robert, Bader, Giovanni, Patalano, Francesco, Banerji, Donald
Publicado 2016

Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study

por Wedzicha, Jadwiga A, Zhong, Nanshan, Ichinose, Masakazu, Humphries, Michael, Fogel, Robert, Thach, Chau, Patalano, Francesco, Banerji, Donald
Publicado 2017

LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD

por Zhong, Nanshan, Wang, Changzheng, Zhou, Xiangdong, Zhang, Nuofu, Humphries, Michael, Wang, Linda, Thach, Chau, Patalano, Francesco, Banerji, Donald
Publicado 2015

Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study

por Wang, Chen, Sun, Tieying, Huang, Yijiang, Humphries, Michael, Bai, Lingyan, Li, Lilly, Wang, Qian, Kho, Pearl, Firth, Roz, D’Andrea, Peter
Publicado 2015